Based on mouse models constructed from the colon cancer cell line CT26 and breast cancer cell line 4T1, the PPARγ agonist rosiglitazone was found to remodel the tumor vasculature system and limit tumor-associated macrophage (TAM) infiltration. The gene discussed is PPARG; the disease is malignant colon neoplasm.